4//SEC Filing
Salek-Ardakani Shahram 4
Accession 0001209191-22-001833
CIK 0001817713other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 5:28 PM ET
Size
5.4 KB
Accession
0001209191-22-001833
Insider Transaction Report
Form 4
Salek-Ardakani Shahram
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2022-01-03+114,250→ 114,250 totalExercise: $20.24Exp: 2032-01-02→ Common Stock (114,250 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option vest on January 1, 2023 and the balance will vest in equal monthly installments thereafter over a three year period.
Documents
Issuer
Janux Therapeutics, Inc.
CIK 0001817713
Entity typeother
Related Parties
1- filerCIK 0001873352
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 5:28 PM ET
- Size
- 5.4 KB